Incidence, Risk Factors, and Outcome of Herpes Zoster in Systemic Lupus Erythematosus

被引:61
作者
Borba, Eduardo F. [1 ]
Ribeiro, Ana C. M. [1 ]
Martin, Patricia [1 ]
Costa, Luciana P. [1 ]
Guedes, Lissiane K. N. [1 ]
Bonfa, Eloisa [1 ]
机构
[1] Univ Sao Paulo, Fac Med, Div Rheumatol, BR-01246903 Sao Paulo, Brazil
关键词
systemic lupus erythematosus; Herpes zoster; infection; viral; risk factors; outcome; SINGLE-CENTER; LONG-TERM; INFECTIONS; CYCLOPHOSPHAMIDE; NEPHRITIS; MORTALITY; SURVIVAL; CHILDREN; VACCINE; SAFETY;
D O I
10.1097/RHU.0b013e3181d52ed7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The incidence and outcome of Herpes zoster (HZ) in systemic lupus erythematosus (SLE) are not completely defined as well as the relevance to HZ of disease and therapy factors. Objective: To determine HZ features in SLE. Patients and Methods: SLE patients ( 1997 update of the American College of Rheumatology classification criteria) with definitive HZ infection were identified from our Lupus Clinic computerized database of 1145 patients. Results: HZ was diagnosed in 51 SLE patients (4.45%) with an annual incidence rate of 6.4 events/1000 patient-years. At HZ diagnosis, mean disease duration was 9.78 +/- 8.37 years, median Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) was 1, and only 17.6% had SLEDAI >= 8. Frequency of manifestations and immunosuppressor use were similar between patients with and without HZ. Forty-two patients (82.5%) with HZ were under prednisone with concomitant immunosuppressive therapy in 66.7%. Thirty-five patients (68.6%) were using immunosuppressors: azathioprine (39.2%), cyclophosphamide (9.8%), and mycophenolate mofetil ( 9.8%). The mean lymphocyte count was 1219 +/- 803/mm(3) (43.1% < 1000/mm(3) and 17.6% < 500/mm(3)). Only patients using azathioprine and cyclophosphamide had lymphocyte counts < 500/mm(3) (15% and 40%). All patients received acyclovir, 19.6% had postherpetic neuralgia, and recurrence occurred in only 7.8%. Thoracic nerves were the most involved site (56.8%) followed by lumbar (23.5%). Bacterial suprainfection occurred in 11.7% but was not associated with therapy, lymphocyte count, or SLEDAI scores ( P > 0.05). Conclusion: This is the largest cohort to determine that HZ is a late SLE complication with some peculiar features, such as good prognosis and typical dermatomal distribution. In addition, we have identified that the major trigger factor for this viral infection in SLE is therapy, particularly the concomitant use of corticosteroid and immunosuppressors, and not active disease.
引用
收藏
页码:119 / 122
页数:4
相关论文
共 42 条
[1]   Safety of vaccination of patients with systemic lupus erythematosus [J].
Abu-Shakra, M. .
LUPUS, 2009, 18 (13) :1205-1208
[2]  
ABUSHAKRA M, 1995, J RHEUMATOL, V22, P1259
[3]   Survival analysis of 306 European Spanish patients with systemic lupus erythematosus [J].
Blanco, FJ ;
Gomez-Reino, JJ ;
de la Mata, J ;
Corrales, A ;
Rodriguez-Valverde, V ;
Rosas, JC ;
de la Camara, AG ;
Pascual, E .
LUPUS, 1998, 7 (03) :159-163
[4]   DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].
BOMBARDIER, C ;
GLADMAN, DD ;
UROWITZ, MB ;
CARON, D ;
CHANG, CH .
ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640
[5]   Infections in systemic lupus erythematosus:: a prospective and controlled study of 110 patients [J].
Bosch, X. ;
Guilabert, A. ;
Pallares, L. ;
Cervera, R. ;
Ramos-Casals, M. ;
Bove, A. ;
Ingelmo, M. ;
Font, J. .
LUPUS, 2006, 15 (09) :584-589
[6]   Morbidity and mortality in systemic lupus erythematosus during a 5-year period -: A multicenter prospective study of 1,000 patients [J].
Cervera, R ;
Khamashta, MA ;
Font, J ;
Sebastiani, GD ;
Gil, A ;
Lavilla, P ;
Aydintug, AO ;
Jedryka-Góral, A ;
de Ramón, E ;
Fernández-Nebro, A ;
Galeazzi, M ;
Haga, HJ ;
Mathieu, A ;
Houssiau, F ;
Ruiz-Irastorza, G ;
Ingelmo, M ;
Hughes, GRV .
MEDICINE, 1999, 78 (03) :167-175
[7]   COMPUTER-ANALYSIS OF FACTORS INFLUENCING FREQUENCY OF INFECTION IN SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
GINZLER, E ;
DIAMOND, H ;
KAPLAN, D ;
WEINER, M ;
SCHLESINGER, M ;
SELEZNICK, M .
ARTHRITIS AND RHEUMATISM, 1978, 21 (01) :37-44
[8]   The nature and outcome of infection in systemic lupus erythematosus [J].
Gladman, DD ;
Hussain, F ;
Ibañez, D ;
Urowitz, MB .
LUPUS, 2002, 11 (04) :234-239
[9]   Herpes Zoster [J].
Cohen, Jeffrey I. .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (03) :255-263
[10]   A retrospective study of the clinical presentation and outcome of herpes zoster in a tertiary dermatology outpatient referral clinic [J].
Goh, CL ;
Khoo, L .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 1997, 36 (09) :667-672